×

Pfizer suffering from patent cliff: Pro

5:50 AM ET Tue, 13 May 2014

Jason Kolbert, head of health care equity research at Maxim Group, says Pfizer's takeover bid is driven by AstraZeneca's pipeline, strategic tax advantages and cost savings.